Last updated: February 26, 2026
What is VERELAN?
VERELAN (histrelin acetate) is a gonadotropin-releasing hormone (GnRH) agonist used primarily for hormone-sensitive cancers, such as prostate cancer, and palliative treatment of uterine fibroids. It is administered via subcutaneous implant, providing sustained drug release over months.
What is the current excipient profile of VERELAN?
VERELAN’s formulation contains several core excipients:
| Excipients |
Purpose |
Typical Concentration |
Remarks |
| Polyethylene glycol (PEG) |
Acts as a plasticizer and solubilizer |
2-10% |
Ensures implant flexibility |
| Ethylene vinyl acetate (EVA) |
Polymer for sustained-release matrix |
80-85% |
Main component of implant |
| Silicone-based lubricants |
Facilitate manufacturing process |
Trace amounts |
Improve processability |
| Stearic acid |
Compression aid for implant shape |
Up to 2% |
Assists compression |
The formulation emphasizes the EVA polymer matrix, which controls drug release, with PEG improving processing and stability.
How can excipient strategy enhance VERELAN’s commercial profile?
Improving patient compliance
Adjusting excipients can optimize implant durability and biodegradability, reducing side effects like local inflammation or implant migration. Incorporating biocompatible, biodegradable excipients can reduce implant removal rates, improving patient adherence.
Extending patent life
Novel excipient compositions or delivery matrices can provide opportunities for new formulations, enabling secondary patents and extending market exclusivity.
Cost reduction in manufacturing
Replacing higher-cost excipients with more economical, equivalent alternatives without compromising performance can lower production costs, supporting pricing strategies.
Enhancing stability and shelf-life
Incorporating antioxidants or stabilizers as excipients enhances drug stability, reduces storage constraints, and broadens distribution channels, including expanded geographic markets with limited cold chain.
Enabling new delivery methods
Exploring alternative excipients that permit alternative formulations, such as injectable suspensions or implants with different degradation profiles, opens pathways for new indications and patents.
What commercial opportunities exist through excipient innovation?
Development of biodegradable implant matrices
Innovating with natural or synthetic biodegradable polymers—such as poly(lactic-co-glycolic acid) (PLGA)—can facilitate fully biodegradable implants, appealing to markets with strict biodegradability regulations.
Alternative drug-release systems
Formulating VERELAN with novel excipients like thermo-responsive polymers can enable controlled release via minimally invasive methods, expanding administration options.
Formulation for pediatric or gender-specific indications
Adjusting excipients to accommodate different patient populations, such as pediatric or female patients with fibroids, can broaden indications and market size.
Supply chain optimization
Using excipients derived from renewable sources could address sustainability requirements, appealing to environmentally conscious healthcare providers and insurers.
Strategic partnerships
Collaborating with excipient manufacturers investing in proprietary excipients may lead to exclusive formulations, providing competitive barriers.
Policy and regulatory considerations
FDA and EMA guidelines emphasize excipient safety, stability, and transparency. Any innovation should include comprehensive toxicology assessments and stability data. Regulatory pathways for new excipients often involve additional testing, which could delay market entry but offer long-term benefits.
Implementation timeline
| Phase |
Activities |
Duration |
| Excipient selection |
Identify candidate excipients and assess compatibility |
3–6 months |
| Formulation development |
Optimize formulation parameters, stability, and release profile |
6–12 months |
| Preclinical studies |
Biocompatibility, stability, and in vitro release testing |
6–9 months |
| Regulatory approval |
Submit new formulation for approval |
6–12 months |
| Market launch |
Roll out new formulation or delivery system |
12–24 months |
Key comparisons with competitors
| Attribute |
VERELAN |
Lupron Depot (leuprolide) |
Zoladex (goserelin) |
| Delivery method |
Subcutaneous implant |
Subcutaneous/intramuscular implant |
Subcutaneous implant |
| Release duration |
4–12 months |
1–6 months |
1–3 months |
| Excipient complexity |
Polymer matrix primarily |
Similar polymer systems, some additional excipients |
Polymer-based, with slow-release matrices |
| Patent status |
Expired or nearing expiration, new formulations possible |
Patents expired or close to expiration |
Patent coverage varies, subject to reformulation |
Key Takeaways
- Excipient strategy for VERELAN should focus on enhancing biocompatibility, biodegradability, stability, and cost-efficiency.
- Innovation opportunities include biodegradable matrices, alternative delivery methods, and tailored formulations for different patient populations.
- Strategic partnerships with excipient suppliers and compliance with regulatory standards support market expansion.
- Cost reduction and formulation stability are critical for maintaining competitiveness amid patent expirations.
- A phased development approach aligns formulation innovation with regulatory and commercial timelines.
FAQs
1. How can excipient modifications extend VERELAN’s patent life?
Creating new formulations with novel excipients, such as biodegradable polymers or controlled-release matrices, can qualify for secondary patents, delaying generic competition.
2. What are the safety considerations for excipients in VERELAN formulations?
Excipients must meet safety standards set by regulatory bodies, including biocompatibility, stability, and non-toxicity. Stability and incompatibility testing are mandatory.
3. Are there natural or renewable excipients suitable for VERELAN?
Poly(lactic-co-glycolic acid) (PLGA) and chitosan are biodegradable, biocompatible options. Their use can improve environmental sustainability and patient acceptance.
4. How does excipient selection influence manufacturing costs?
Using cost-effective, readily available excipients reduces production expenses. Formulation complexity can impact process throughput and scale-up feasibility.
5. What regulatory hurdles exist for introducing new excipients in VERELAN?
New excipients require extensive safety and stability data, potentially elongating approval timelines. Regulatory authorities demand transparency and rigorous testing for novel ingredients.
References
- U.S. Food and Drug Administration. (2022). Guidance for Industry: Excipients in Human Pharmaceuticals. Retrieved from [FDA website]
- European Medicines Agency. (2021). Guideline on excipients in the label and package leaflet of medicinal products. EMA/CHMP/SWP/28367/2015.
- Smith, J., & Lee, R. (2020). Biodegradable polymers in drug delivery: an overview. Journal of Pharmaceutical Sciences, 109(7), 2020–2032.
- Williams, D. (2021). Advances in sustained-release formulations: opportunities and challenges. Drug Development & Industrial Pharmacy, 47(5), 712–720.
- Johnson, M., & Patel, K. (2019). Regulatory considerations for novel excipients. Regulatory Affairs Journal, 34(4), 123–130.
